Skip to content

Excision Limits of Oral Cavity Tumor by Narrow Band Imaging

Excision Limits of Oral Cavity Tumor by NARROW BAND IMAGING (NBI): Feasibility Trial

Status
Terminated
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01198119
Acronym
NBI-CAB
Enrollment
23
Registered
2010-09-09
Start date
2010-07-01
Completion date
2014-12-31
Last updated
2026-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Keywords

oral cavity tumor, narrow band imaging, subclinical cancer lesion

Brief summary

This study evaluates the feasibility of the NBI technique in the detection of early cancer lesions.

Interventions

DEVICELocation of the suspected lesions

The suspected lesions will be located before the excision, during the surgery. 1. With traditional light 2. NBI technique The images will be recorded and compared

PROCEDUREBiopsy

In case of suspected lesions detected by the NBI technique, this area is biopsied

PROCEDURELesion excision/Surgery

In case of positive biopsy, the suspected lesions is excised

Sponsors

Centre Oscar Lambret
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Primitive epidermoid cancer of the oral cavity, proved by histology, not treated previously, patient having a surgery * No previous surgery for this cancer * Age \> 18 years * Patient affiliated to health insurance * Consent signed by the patient

Exclusion criteria

* Metastatic or recurrent disease * Health care impossibilities for geographic, social, psychic reasons

Design outcomes

Primary

MeasureTime frameDescription
Reliability for detection of subclinical lesionsbaselineConcordance between the histological data and the lesions detected by the NBI technique

Secondary

MeasureTime frameDescription
Excision limits quality criteriabaselinepercentage of detection / percentage of false-negative
Detection of suspect lesionsbaselineIdentify the detection of suspect lesions, aloof from the primitive lesion (percentage of detection / percentage of true-positive)

Countries

France

Contacts

PRINCIPAL_INVESTIGATORSophie EL BEDOUI, MD

Centre Oscar Lambret

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 17, 2026